The Cancer Pharmacology Core provides the necessary expertise and resources to design and undertake pharmacokinetic (PK) studies in Phase I and II clinical trials, and preclinical investigations. Services include the implementation and validation of previously developed analytical methods to quantify drugs and their metabolites in biological fluids, and modification or development of new assays. The Core also offers comprehensive analysis of pharmacokinetic data, including the estimation of pharmakinetic (PK) parameters and identifying their relationship to pathophysiological variables and pharmacodynamic effects. J. Supko (MGH) has led this facility since 2004. Director: Jeffrey G. Supko, PhD(MGH) Category: 1.37 (Pharmacokinetics &Drug Metabolism), 4.05 (Pharmacology) Management: Joint (Cancer Center and Institutional).
Pharmacokinetic (PK) studies are widely recognized as being essential to the development and evaluation of new drugs and combination regimens for the treatment of cancer. The Cancer Pharmacology Core provides DF/HCC investigators with all of the necessary capabilities to design and undertake PK studies in the context of preclinical investigations and early phase clinical trials. The ultimate goal of the Core is to facilitate the acquisition of informative PK data, that has a direct relevance to the clinical or preclinical evaluation of investigational chemotherapeutic agents, and make the data available to investigators in a timely manner.
Showing the most recent 10 out of 411 publications
